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•  Impaired spinal growth 
•  Epilepsy 
•  Most common pediatric CNS malignancy 
•  Targets the cerebellum during early development 
•  400-450 new cases per year 
•  4 Subgroups: WNT, SHH, Group 3, Group 4 
Treatment 
•  Craniospinal irradiation 
•  Surgical resection 
•  Aggressive 
chemotherapy 
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•  We observed ARHGAP36 mutation and deletions of various sizes 
in addition to reduced expression with this system. 
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Exon 2 Sequence Alignment  
Results 
Figure 4. A) Agarose gel images of PCR for exon 2, exon 8 and KO 
flanking primers in 293T and Ons76 clones. B) Western blot 
showing reduced ARHGAP36 expression in 293T #3 and Ons76 #3 
clones. C) Sequence alignment of 293T and Ons76 clones with WT 
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Figure 3. Schematic of transfection and selection techniques. 
piggyBacTM transposase and dual gRNA/Cas vector were lipofected into 
Ons76 and 293T cell lines. Doxycycline was added to transcribe the Cas9 
enzyme and induce cutting. Puromycin was added to select for transfected 
clones. Clones were picked and analyzed for deletions and mutations 
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Modified from Larson, J., et al. (currently under review) 
Figure 1. Sleeping Beauty insertional mutagenesis screen for MB.  
A) Mouse model development driven by Nestin-cre recombinase 
generating mice with Pten or p53 conditional deficiencies. B) Schematics 
of Nestin-Cre, SB11 transposon, and T2/Onc constructs. C) Arhgap36 
common insertion sites and MB stained cerebellum. D) Arhgap36 
emerges as top candidate driver gene for MB. 
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Figure 2. A) Map of CRISPR/Cas9 vector with dual gRNAs specific for 
ARHGAP36 exon 2 and exon 8. B) Schematic of piggyBacTM transposition 
of CRISPR/Cas vector. C) Mechanism of gRNA directed Cas9 making 
double stranded breaks in ARHGAP36. Non-homologous end joining 
results in gene deletion or base pair mutations. 
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D) Schematic of primer binding pairs for PCR. 
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